HPLC method development for determination of metoprolol, telmisartan and cilnidipine simultaneously using response surface design

Abstract

The development of an HPLC method for determination of Metoprolol, Telmisartan and Cilnidipine simultaneously in additional dosage was not published or reported up till date. The main aim of our study was to design a simultaneous and multiple response optimizations using the Derringer's desirability function in order to estimate Metoprolol, Telmisartan and Cilnidipine in pharmaceutical and bulk drug dosage form by HPLC method with experiment central compositive design (CCD) protocol for the quantitative methods analysis and also for validation of the procedure that is developed as per ICH regulations. An innovative RP-HPLC method had been designed for the estimation of Metoprolol, Telmisartan and Cilnidipine simultaneously in formulation using central composite design. Three factors were investigated and determined as significant when compared to the interaction and quadratic effect of the samples that CCD along with the response of the surface methodology. The developed method produced a good resolution of the drugs with a very short run time of 7.5 min. It was also validated according to ICH guidelines. It was recognized as novel and simple method that is accurate and cost-effective. So the proposed method fits best in the assaying routine of Metoprolol, Telmisartan and Cilnidipine in any formulations produced by quality control laboratories.